About Us > Panel of Advisors

Panel of Advisors

Our advisors worked the majority of their careers in the healthcare field: studying diseases, developing medical and dental technologies, managing tissue banks.

Howard Greenman

Mr. Greenman was most recently Vice President and Interim CEO for HealthCare IT, Inc. (HCIT) – a biomedical software and services firm specializing in human tissue banking. While at HCIT, he formed partnerships with global pharmaceutical companies as well as major academic medical institutions to standardize the management of donated human specimens by using advanced logistics and clinical data management software and protocols. Prior to HCIT, Mr. Greenman led the strategic marketing function for Philips Medical System's Remote Patient Management Division, part of Philip's New Ventures organization. In this role, Mr. Greenman was responsible for commercialization and partnership strategy for a cardiovascular disease management platform technology. Prior to Philips, Mr. Greenman was Director of Business Development for Ardais Corporation, a biorepository management company that set the standard in tissue banking bioethics, logistics, and quality by building one of the largest repositories of research quality commercially available cancer tissue in the world. Mr. Greenman was the founder of medXtend Corporation, a venture backed healthcare services company providing medical devices and services for use by Radiologists and Primary Care Physicians. Additionally, Mr. Greenman worked in a variety of healthcare consulting roles within Accenture's Healthcare Practice, KPMG Peat Marwick's Healthcare Strategy Group, Oracle, and the Boston Consulting Group.

Mr. Greenman holds an M.B.A. from the Wharton School of Business in Healthcare Management.
Back to Top ↑

Dr. Peter Verlander

Dr. Verlander was most recently the Associate Director for Strategic Development of the Laboratory for Molecular Medicine (LMM) within the Harvard Medical School - Partners Healthcare Center for Genetics and Genomics, where he helped transform the vision of personalized medicine into reality by translating research discoveries into breakthrough molecular diagnostic tests. Dr. Verlander led the team that developed the first clinical test for detection of EGFR mutations predicting therapeutic response in lung adenocarcinoma. Dr. Verlander is a molecular geneticist with nearly 15 years of experience in various aspects of human genetics in both academia and industry, including research at The Rockefeller University in New York on the molecular genetics of Fanconi anemia (FA), a DNA breakage disorder leading to bone marrow failure and increased risk of leukemia. In 2000, Dr. Verlander came to Boston to join Millennium Predictive Medicine's Patient Management effort before joining the LMM in 2003.

Dr. Verlander received his PhD in Microbiology from Duke University.
Back to Top ↑

Dr. Jeffrey Gruneich

Dr. Gruneich was most recently a World Wide Provider Solution Sales specialist in IBM Healthcare and Life Sciences, focused on translational medicine and biobanking. He worked with government, pharmaceutical, biotechnology, and academic organizations to foster complex relationships and partnerships in support of their strategic goals. As an example, Dr. Gruneich worked closely with a cancer-focused patient advocacy group to identify key strategic objectives which ultimately led them to support and fund a biobanking collaboration between multiple medical centers and researchers across the country. Prior to joining IBM, Dr. Gruneich was Chief Business Officer of Infoceutics, Inc., an anti-microbial bioinformatics company. He also co-founded and was Chief Strategy Officer for eTechtransfer.com, an online exchange for licensing life science intellectual property. He worked as a research scientist developing new immunodiagnostic tests for Charm Sciences.

Dr. Gruneich received his PhD in Bioengineering from the University of Pennsylvania, developing new gene therapy technologies.
Back to Top ↑

Mr. James Sigler

Mr. Sigler was formerly a director of ViaCord (now part of PerkinElmer). Mr. Sigler has over 24 years of management experience, including 18 years in the development, manufacturing, and quality management of biological, cell therapy, and small molecule products. As an example, he was divisional head of manufacturing when Genzyme Corporation sought and received regulatory approval for Carticel, an autologous cell therapy product.

Mr. Sigler earned an MBA degree from Harvard Business School and a B.S. degree from Cornell University.
Back to Top ↑

  About Us  
  Our Laboratory  
  Contact Us